Positioning of Old and New Therapies in IBD

Content Type: presentation

Presenter: David T. Rubin, MD, FACG

Presenter Disclosure: Advisory Committee/Board Member: CCFA, Janssen Consultant: AbbVie Pharmaceuticals, Abgenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-cap, Dizal Pharmaceuticals, Galen Pharma/Atlantica, Genentech, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), GSK, Janssen, Lilly, Narrow River Mgmt., Pfizer, Prometheus, Reistone, Shire, Takeda, Techlab, Inc. Employee: Cornerstones Health Inc. (non-profit medical education company), GoDuRn LLC (non-profit medical education company) Grant/Research Support: AbbVie Pharmaceuticals, Genentech, Janssen, Prometheus Laboratories, Shire, Takeda Co-Founder: Cornerstones Health Inc. (non-profit medical education company), GoDuRn LLC (non-profit medical education company) Royalties: Slack Publications

Event: ACG Virtual Grand Rounds

Release Date: 5/29/2020

Expiration Date: 5/29/2023

Objective: Choose therapies based on prognosis and confirm effectiveness. Identify targets of treatment that are individualized based on patient symptoms and objective measures of disease activity.